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The Malaria Policy Advisory Committee to the World Health Organization met in Geneva, Switzerland from 11 to
13 September, 2012. This article provides a summary of the discussions, conclusions and recommendations from
that meeting.
Meeting sessions included: updated policy recommendations on the use of sulphadoxine-pyrimethamine for
Intermittent Preventive Treatment of malaria in pregnancy, as well as the use of single dose primaquine as a
Plasmodium falciparum gametocytocide; the need to develop a Global Technical Strategy for Malaria Control and
Elimination 2016– 2025 and a global strategy for control of Plasmodium vivax; the Affordable Medicines Facility for
malaria independent evaluation and promoting malaria case management in the private sector; updates from
the Technical Expert Group on drug resistance and containment and the Evidence Review Group on malaria
burden estimation; update on the RTS,S/AS01 malaria vaccine; progress on the policy setting process for malaria
vector control; and the process for updating the WHO Guidelines for the Treatment of Malaria.
Policy statements, position statements, and guidelines that arise from the MPAC meeting conclusions and
recommendations will be formally issued and disseminated to World Health Organization Member States by the
World Health Organization Global Malaria Programme.
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The Malaria Policy Advisory Committee (MPAC) to the
WHO met from 11 to 13 September 2012 in Geneva,
Switzerland, following its inaugural meeting in February
2012 [1]. This article provides a summary of the discus-
sions, conclusions and recommendations from that
meeting a as part of the recently established Malaria
Journal thematic series “WHO global malaria recom-
mendations” [2].
The following sections of this article provide details
and references for the background documents presented
at the open meeting sessions of the committee on: the
use of sulphadoxine-pyrimethamine for Intermittent
Preventive Treatment of malaria in pregnancy (IPTp-SP);* Correspondence: mpacgmp@who.int
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CH-1211 Geneva 27, Switzerland
© 2012 WHO Malaria Policy Advisory Committ
distributed under the terms of the Creative Co
permits unrestricted use, distribution, and repthe use of single dose primaquine as a Plasmodium fal-
ciparum gametocytocide; the need for a Global Technical
Strategy for Malaria Control and Elimination 2016– 2025
and a global strategy for control of Plasmodium vivax;
the Affordable Medicines Facility for malaria (AMFm)
independent evaluation and promoting malaria case
management in the private sector; updates from the
Technical Expert Group (TEG) on drug resistance and
containment and the Evidence Review Group (ERG) on
malaria burden estimation; update on the RTS,S/AS01
malaria vaccine; progress on the policy setting process
for malaria vector control; and the process for updating
the WHO Guidelines for the Treatment of Malaria.
The MPAC discussion and recommendations related
to these topics, which took place partially in closed ses-
sion, are also included. MPAC decisions are reached byee and Secretariat; licensee BioMed Central Ltd. This is an Open Access article
mmons Attribution License (http://creativecommons.org/licenses/by/2.0), which
roduction in any medium, provided the original work is properly cited.
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to 15 March 2013 [4].
Report from the WHO Global Malaria Programme
The Director of the WHO Global Malaria Programme
(WHO-GMP) updated MPAC members on progress
with recommendations from their last meeting [5], in-
cluding the finalization of the policy recommendation
on Seasonal Malaria Chemoprevention (SMC) [6] and
on the interim position statement on larviciding in sub-
Saharan Africa [7].
Since the previous MPAC meeting, WHO-GMP has
launched the Global Plan for Insecticide Resistance Man-
agement in malaria vectors (GPIRM) [8] on 15 May
2012. In addition, the WHO Director-General launched
two new manuals: Disease Surveillance for Malaria Con-
trol and Disease Surveillance for Malaria Elimination in
Namibia on World Malaria Day [9]. The Director-
General also used that day to launch a new initiative led
by WHO-GMP, entitled “T3: Test. Treat. Track”, which
calls for every suspected case of malaria to receive a
diagnostic test, every confirmed case to be treated with
an effective quality-assured medicine, and for the disease
to be tracked using a timely and accurate surveillance
system [10]. Other important departmental activities dis-
cussed included capacity building, Country Malaria
Programme Reviews, the development of an Elimination
Scenario Planning tool (together with the Clinton Health
Access Initiative and the Global Health Group), the
launch of a series of Elimination Case Studies (together
with the Global Health Group and National Malaria
Control Programmes) [11], the revision to the handbook
for the management of severe malaria, a new project to
provide support to five African countries on scale-up of
Integrated Community Case Management (iCCM) [12],
and the plans for the World Malaria Report 2012. Also
provided were an overview of changes in the global land-
scape for malaria control and elimination including fi-
nancial challenges; changes within the Global Fund; the
work to gather existing documents into a “malaria in-
vestment toolkit”; and a major event, “Malaria 2012”,
convened by the Government of Australia to focus on
the opportunities and challenges for malaria control and
elimination in the Asia-Pacific region [13].
MPAC commended the work of GMP, as well as the
ERGs and TEG that had been convened since its inaug-
ural meeting. The next update to MPAC will focus on
results from the World Malaria Report 2012, and will in-
clude updates from the WHO Regional Offices.
Intermittent preventive treatment of malaria in
pregnancy using sulphadoxine-pyrimethamine (IPTp-SP)
WHO-GMP, at the recommendation of MPAC, con-
vened an ERG on IPTp-SP from 9 to 11 July, 2012 inGeneva [14,15]. The conclusions of the evidence review
group [16,17] on the current efficacy and effectiveness of
IPTp with SP, which is WHO policy, were evaluated by
MPAC. The review indicates that in sub-Saharan Africa,
in spite of the increased prevalence in P. falciparum of
molecular markers associated with resistance to SP
(based on the prevalence of quintuple mutant dhps/dhfr
haplotypes), IPTp-SP remains effective at preventing
peripheral parasitaemia, maternal anaemia, and clinical
malaria during pregnancy and is associated with reduced
neonatal mortality as well as reduced incidence of ad-
verse pregnancy outcomes.
MPAC members agreed with the conclusions of the
review, which included new evidence of increased effect-
iveness of multiple doses of SP (median four) compared
to two doses. They endorsed an update of the current
recommendation, aiming to improve coverage of and in-
crease access to IPTp with SP as part of routine ante-
natal care services. The MPAC also recommended that
IPTp with SP should still be administered to women in
areas of moderate to high malaria transmission in Africa
including those where P. falciparum parasites carry
quintuple mutations linked to SP resistance.
The updated IPTp-SP policy, which will be communi-
cated subsequently to countries by WHO, is as follows
[18]:
In areas of moderate-to-high malaria transmission,
IPTp with SP is recommended for all pregnant women
at each scheduled antenatal care visit, except during the
first trimester. WHO recommends a schedule of four
antenatal care visits.
a) The first IPTp-SP dose should be administered as
early as possible during the 2nd trimester of
gestation;
b)Each SP dose should be given at least one month
apart;
c) The last dose of IPTp with SP can be administered
up to the time of delivery, without safety concerns.
IPTp should ideally be administered as directly
observed therapy (DOT); SP can be given either on an
empty stomach or with food; folic acid at a daily dose
equal or above 5 mg should not be given together with
SP as this counteracts its efficacy as an anti-malarial;
instead, WHO recommends daily iron and folic
acid supplementation in pregnant women at the dose of
30–60 mg of elemental iron and 0.4 mg of folic acid,
to reduce the risk of low birth weight infants, maternal
anaemia and iron deficiency at term. SP should not
be administered to women receiving co-trimoxazole
prophylaxis.
MPAC noted that although transmission of malaria
has been reduced substantially in some countries where
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sence of information on the level of malaria transmission
below which IPTp-SP is no longer cost-effective, such
countries should not stop IPTp.
MPAC concluded that monitoring of IPTp-SP effect-
iveness and safety of multiple doses is essential and
should continue. However, research is ongoing to define
the best methodology for such monitoring; this will be
shared when available. There is currently insufficient evi-
dence to support a general recommendation for the use
of IPTp-SP outside Africa.
MPAC suggested that the updated recommendation
on IPTp-SP, now finalized and available on the WHO-
GMP website [18], should include a brief contextual pre-
amble in addition to the appropriate footnotes. It will
subsequently be communicated to relevant countries by
WHO-GMP.
Primaquine single dose as a P. falciparum gametocytocide
The ERG on the use of single dose primaquine as a P.
falciparum gametocytocide [19,20], convened by WHO-
GMP at the recommendation of MPAC, presented a
summary of their 13 to 15 August, 2012 meeting in
Bangkok, Thailand, and the conclusions of their evi-
dence review on the safety and effectiveness of prima-
quine as a gametocytocide for P. falciparum [21,22].
WHO already recommends single dose primaquine
(0.75 mg base/kg) for uncomplicated P. falciparum mal-
aria, as a component of pre-elimination or elimination
programmes, provided that the risks of haemolysis in
glucose-6-phosphate dehydrogenase (G6PD) deficient
patients are considered.
Although the evidence suggests that primaquine as a
gametocytocidal drug can potentially reduce malaria
transmissibility, especially in efforts to eliminate P. fal-
ciparum malaria, the effect on reducing malaria trans-
mission using primaquine requires that a very high
proportion of people with P. falciparum infection receive
it. The concerns related to acute haemolytic anaemia in
G6PD-deficient patients and the limited availability of
G6PD testing in the field have hampered the successful
implementation of this recommendation.
The ERG review suggests that a single 0.25 mg base/kg
is effective in reducing transmission and is unlikely to
cause serious toxicity in subjects with any of the G6PD
variants [21]. How to communicate this clearly – that a
lower dose of primaquine is effective and safe and can be
administered without G6PD testing – and without causing
confusion was the subject of much discussion. MPAC
recognized that this recommendation may raise the issue
of whether countries already using a single dose of
0.75 mg base/kg primaquine in the treatment of P. falcip-
arum malaria (the current WHO recommendation)
should consider changing to the lower dose. Theconclusion was that these countries should continue with
the 0.75 mg base/kg policy until additional information on
the efficacy of the lower dose is available, at which time
WHO would review the recommendation for these
countries.
For countries which had either: (a) areas threatened by
artemisinin resistance where single dose primaquine as a
gametocytocide for P. falciparum malaria is not being
implemented; and/or (b) elimination areas which have
not yet adopted primaquine as a gametocytocide for P.
falciparum malaria, MPAC recommended that a single
primaquine dose of 0.25 mg base/kg be given to all
patients with parasitologically-confirmed P. falciparum
malaria on the first day of treatment, in addition to an
artemisinin-based combination therapy (ACT) drug, ex-
cept for pregnant women and infants <1 year of age.
The updated recommendation has since been finalized
and is available on the WHO-GMP website [23]. It will
subsequently be communicated to relevant countries by
WHO-GMP. The full evidence review will be published
as a WHO publication.
Developing a global technical strategy for malaria control
and elimination 2016– 2025
The Global Malaria Action Plan (GMAP) was launched
by the Roll Back Malaria (RBM) Partnership in 2008 fol-
lowing a consultative process with a wide range of stake-
holders. While the GMAP does not contain an end date,
there has been a request by some members of the
RBM Board to consider revising the GMAP before
the end of 2015. This will be a point for discussion at
the December 2012 RBM Board meeting.
The question posed to MPAC by WHO-GMP for its
September session was whether the collection of WHO
policy recommendations for malaria is sufficiently clear
as they are now, or whether an over-arching review of
the strategy mix should be commissioned by WHO-
GMP under the oversight of the MPAC [24]. This strat-
egy mix would help underpin any revisions to the
GMAP, which would focus on the advocacy, resource
mobilization and partner harmonization required to sup-
port countries to implement the recommended technical
strategy.
MPAC supported the idea that WHO-GMP should de-
velop what it called a Global Technical Strategy for Mal-
aria Control and Elimination, 2016–2025, a period
which was perceived as a reasonable and feasible time
frame. The concept of stratification and district (periph-
eral) capacity for malaria control should be central to
such an approach. It would also be an opportunity to re-
view a “menu” of options at the country level and con-
sider prioritization, particularly the need for surveillance,
monitoring, evaluation, and research. MPAC stressed
that it was important to have a bottom-up, country
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suggested that an ERG be convened to provide the tech-
nical input for the intervention mix and stratification
that would be central to the new strategy.
MPAC also strongly supported the idea of a revised
GMAP that had buy-in from a broad range of stake-
holders and sectors. Key suggestions included that it
should: (a) be based on a foundation of the WHO Global
Malaria Technical Strategy for Malaria Control and
Elimination, 2016–2025; (b) address financial and oper-
ational elements; (c) be a concise document; (d) RBM
and WHO should work closely together in its develop-
ment; and (e) its goals should be realistic and
measurable.
There was consensus from MPAC members and
observers that what is needed today is different from
what was needed when GMAP was first launched. At
that time the focus was on scale-up, and GMAP
provided a useful umbrella for this. At present, the new
focus should address the heterogeneity and changing dy-
namics of malaria in order to secure continued progress
and in particular, guide countries and regions. MPAC
concluded that there was a need for WHO to play a
stronger role in providing clear technical strategies to
countries, who struggle to reconcile divergent technical
guidance, particularly with regard to elimination.
Although MPAC saw developing technical strategies
as a core function of WHO-GMP, it advised that any
“roadmap to eradication”, currently also under consider-
ation by the global malaria community, would be so far-
reaching in its depth and breadth, that it was beyond the
capacity of WHO-GMP alone, or any single organization
for that matter, to address at this point in time. MPAC
advised that any roadmap to eradication be kept separ-
ate, but that via its Global Technical Strategy for Malaria
Control and Elimination 2016–2025, and through other
mechanisms, WHO-GMP should be a critical partner in
the process for constructing any detailed roadmap.
Global strategy for Plasmodium vivax control
and elimination
A plan to develop a global strategy for P. vivax control
and elimination was presented to MPAC as a follow up
to a discussion from its inaugural meeting [25]. Because
P. vivax is not perceived to be a major killer compared
to P. falciparum, it is seldom addressed explicitly in mal-
aria strategies and technical documents, and often fea-
tures as an add-on to strategies primarily designed for
P. falciparum.
MPAC agreed with the premise that a global strategy
for P. vivax malaria was urgently needed, and although
it should fall under the umbrella of the overall Global
Technical Strategy for Malaria Control and Elimination,
2016–2025, it needed to be commissioned as a separatepiece of work to ensure that it is fully developed. How-
ever, the depth of work required to pull the strategy to-
gether is beyond the scope of a regular ERG. MPAC
agreed with the proposed method of work, in particular
establishing a small steering committee to shape the
work required, and the hiring of a consultant to support
the entire process, including facilitating the convening of
one or more ERGs as required.
A small steering committee, to be convened by WHO-
GMP, will guide the development of a global strategy for
P. vivax control and elimination and will be convened
before the end of 2012; an update will be provided to
MPAC at its next meeting.
Affordable Medicines Facility for malaria (AMFm)
and promoting malaria case management in the
private sector
Briefings on the AMFm, the future of which was under
review by the Global Fund Board at the time, were pre-
sented by WHO-GMP [26] and by the Chair of the Glo-
bal Fund Working Group and RBM Task Force on
AMFm [27]. Since the MPAC is not involved with fund-
ing decisions for the AMFm, discussion focussed on the
broader issue of promoting access to quality care in the
private sector. The following is a summary of MPAC
recommendations regarding malaria case management
in the private sector:
a) Access to affordable and quality assured malaria
diagnostic testing, notably Rapid Diagnostic Tests
(RDTs), should be an integral part of all initiatives
aiming at improving access to ACT in both the
private and the public sectors.
b) The primary aim of new global initiatives on malaria
case management in the private sector should be a
holistic approach to improving the management of
febrile children, providing access to malaria
diagnostic testing and appropriate treatment for
malaria and non-malaria febrile illnesses.
c) The priority for access to subsidized medicines and
diagnostics should be given to young children, the
group at highest risk.
d) The specific country context should be taken into
account in the design and implementation of
initiatives aiming at subsidizing medicines and
diagnostics, in particular differences in health
systems, such as access to health care facilities,
proportional role of the private sector in providing
care, and availability of community-based health
services.
e) In designing new initiatives on malaria case
management in the private sector, the increased risk
of selection and spread of anti-malarial drug
resistance (to both artemisinins and partner
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in place to ensure targeting of ACT to confirmed
malaria patients.
f ) More evidence is required with high quality data in
relation to the public health targets of AMFm,
especially information on use of co-paid quality
assured ACT, to provide informed decisions on the
public health value of this initiative.
g) Countries which have been included in the pilot
phase of AMFm should be supported during the
transition phase, building on the lessons learnt.
h) Further opportunities for closer collaboration and
interactions between public and private sectors,
some of which emerged in AMFm Phase I, should
be further explored especially for peripheral health
care settings.
i) New initiatives aimed at improving malaria case
management in the private sector should have strong
components of education, behaviour change, training
and communication to promote wider use of
diagnostics and adherence to test results.
j) All future initiatives including subsidies for ACT and
RDTs should be designed with careful attention to
mechanisms to ensure sustainability.
Drug resistance and containment
Members [28] of the newly created standing TEG on
drug resistance and containment met for the first time
from 21 to 22 June 2012, based on the recommendation
of MPAC at its inaugural meeting and the subsequent
approval of the terms of reference of the TEG [29]. A
summary of the meeting and the TEG’s recommenda-
tions were presented to MPAC for information and
discussion. Updates were presented on monitoring anti-
malarial drug efficacy and capacity strengthening, as well
as on containment activities, including: a review of the
current working definition of artemisinin drug resist-
ance; potential modifications to existing containment
strategies; artemisinin resistance outside the Greater
Mekong sub-Region; and gaps in research for anti-
malarial drug resistance monitoring and containment ac-
tivities [30,31].
Based on the reviewed data, the TEG concluded that
there is currently no evidence of artemisinin resistance
outside the Greater Mekong sub-Region; however the
TEG recommended continued and intensified surveil-
lance on ACT efficacy outside the Greater Mekong sub-
Region and encouraged consultation with the TEG by
WHO-GMP whenever new data raise concerns.
MPAC commended Cambodia, which has officially
declared elimination as the objective of its anti-malaria
programme. In the areas of western Cambodia, which
are most affected by artemisinin resistance, the disease is
now present in a few foci with low incidence. WHO-GMPwill support the Ministry of Health in planning for elimin-
ation of P. falciparum malaria in these foci within a defined,
short time-span.
MPAC supported that mass drug administration be
considered as a potentially effective additional measure
to achieve elimination rapidly as a containment strategy
in such areas. However, pilot studies on mass drug ad-
ministration for containment of artemisinin resistant
malaria, as recommended by WHO following an infor-
mal consultation of experts in 2010, have not been
implemented yet. MPAC recommended that WHO-
GMP should work with National Malaria Control Pro-
grammes (NMCPs) to implement one or more pilot
studies to assess coverage, effectiveness, safety and other
operational issues related to mass drug administration.
They also supported the TEG recommendation that one
or two NMCP representatives from the Greater Mekong
sub-Region be invited to be members of the TEG.
Malaria burden estimation
Measuring progress in reducing global malaria burden is
partially accomplished through the production of esti-
mates of the number of malaria cases and deaths such as
those produced by WHO in the World Malaria Report,
as well as those reported by other groups. The specific
tasks for the ERG on malaria burden estimation, created
on the recommendation of MPAC at its inaugural meet-
ing and as outlined in its terms of reference [32], include
mapping a way forward in producing malaria burden
estimates. The focus was on the use of estimates by
WHO Member States and their development partners,
as well as describing how to obtain better data for input
into those estimates, which can be a challenge [1].
ERG members [33] met for the first of three planned
meetings from 27 to 28 June, 2012. As part of its update
to MPAC, the ERG Chair described the group’s general
timeline, progress to date, and future work [34]. Cur-
rently, three meetings are scheduled over approximately
18 months, with supportive work to be done by group
members in between. The first meeting [35] was
designed to outline relevant issues, the second to elicit
further expert opinion, especially from groups directly
involved in malaria burden estimation, and the third to
develop recommendations to MPAC on the way forward,
which will be included in the final meeting report. The
objective is to ameliorate the problems with malaria bur-
den estimation in the short term, and to move towards
solving them in the long term.
MPAC members acknowledged that the task of the
ERG was ambitious, but said that given the weaknesses
of current methods, which are most challenging where
burden is greatest, consistency and improvements in
malaria burden estimation would be invaluable for
prioritization and resource allocation. This view was
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particularly donors, who also suggested that it would be
helpful to make clear that as methods have improved
and been utilised, previous estimates have been changed
retrospectively so that they are comparable.
The issue of how to communicate uncertainty in esti-
mates to politicians, the media, and the public was also
discussed. MPAC members stressed that the purpose of
the review was not to create a competition among meth-
ods, but rather to move in the direction of creating a
balance of what methods would be most useful and most
feasible at the international level. All members of the
global malaria community need to work collaboratively
in better communicating uncertainty for any type of esti-
mation to non- malaria specialist audiences.
This ongoing ERG will next update MPAC on its pro-
gress at their meeting from 13–15 March 2013.
RTS,S/AS01 malaria vaccine
RTS,S/AS01, the most advanced vaccine candidate
against P. falciparum, is currently being evaluated in a
pivotal Phase 3 trial. In its update to MPAC [36,37], the
Joint Technical Expert Group (JTEG) on Malaria Vac-
cines [38], first convened in June 2009 by WHO-GMP
and the WHO Department of Immunization, Vaccines &
Biologicals (WHO-IVB), described RTS,S/AS01 results
to date, the timing of further Phase 3 results, the
intended target population for deployment, and the tim-
ing for any policy recommendations.
The JTEG has determined that there should be suffi-
cient data available to make a draft policy recommenda-
tion regarding RTS,S/AS01 in 2015 for subsequent
consideration by the policy advisory committees in
WHO-IVB (Strategic Advisory Group of Experts -SAGE)
and GMP (MPAC). RTS,S/AS01 will be considered as an
addition to, not a replacement for, existing preventive
and treatment measures. MPAC will have a key role in
the decision whether RTS,S/AS01 should be added to
the current range of malaria prevention measures and, if
so, in which epidemiological situations. SAGE will have
a key role for recommendations regarding adding RTS,
S/AS01 to routine immunization programmes, its sched-
ule, and ensuring satisfactory co-administration data.
A joint MPAC/SAGE session has been tentatively
agreed for April 2015; confirmation depends on results
made available to WHO in 2014. Given the apparent
waning of vaccine efficacy over time against the first or
only episode of clinical malaria, the JTEG highlighted
the need for further analyses to explore duration of pro-
tection in the full trial results to be received in 2014.
The WHO policy recommendation will take into consid-
eration safety and efficacy results from the current Phase
3 efficacy trial after a 30-month follow-up of children
who have received the malaria vaccine together withroutine infant vaccines, as well as site-specific data on
efficacy (where there is adequate power), 18-month
booster dose efficacy, and protective efficacy against se-
vere malaria.
Proposed policy setting mechanisms for malaria vector
control
WHO-GMP updated MPAC on progress and challenges
in malaria vector control; potential threats and the need
for new tools and technologies; and the establishment of
a Vector Control Advisory Group (VCAG) to facilitate
the review of new paradigms in vector control for both
malaria and neglected tropical diseases. WHO-GMP also
proposed potential alternatives for advisory mechanisms
beyond VCAG to address broader gaps in policies
for malaria vector control [39,40], in particular the tech-
nical guidance for malaria vector control programmes
since VCAG, as a non-malaria specific body, is not
designed to address the full range of malaria vector con-
trol policy issues.
After being asked to consider whether to establish a
standing TEG for malaria vector control or to convene
time-limited ERGs as the need for specific policy deci-
sions arises, and following clarifications regarding the
roles of the various malaria vector control groups,
MPAC recommended that there is a need for a standing
TEG; ERGs may also be convened as needed.
Following MPAC inputs on the structure of the TEG
and a review of existing TEGs [41], terms of reference
have since been finalized and are available on the WHO-
GMP website. A call for expressions of interest in TEG
membership will be disseminated by WHO-GMP.
Chemotherapy TEG and process for updating WHO
Guidelines for the Treatment of Malaria
The terms of reference for the TEG on malaria chemo-
therapy, a group that pre-dates the creation of MPAC,
were presented to MPAC for approval [42] in order to
be in line with the new structure and process for global
malaria policy setting. They were agreed and have been
published on the WHO-GMP TEG webpage [43]. After
extensive discussion, there was agreement that the TEG
should remain a single group, encompassing both treat-
ment and chemoprevention. A proposal for rotating
membership was also discussed and agreed, so that there
will be overlap between current and new members, par-
ticularly in light of the soon-to-be-updated WHO
Guidelines for the Treatment of Malaria, which will be a
significant part of the TEG’s work in 2013.
The full process for reviewing and updating the WHO
Guidelines for the Treatment of Malaria were presented
and discussed in detail [44,45]. Several suggestions were
made to improve the format of what will be the third
edition of the Guidelines, including adding clear
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of languages in which the guidelines are published (cur-
rently English, French, and Spanish). WHO-GMP wel-
comed any further feedback or suggestions from the
global malaria community that would improve the third
edition of these Guidelines.
Discussion
The wording for policy recommendations were finalized
by MPAC during their closed session and via email fol-
lowing the meeting; conclusions have been included in
the summaries of the meeting sessions above, and links
to the full recommendations have been provided as
references. Depending on the agenda for the next MPAC
meeting, time allocated to the closed session might be
increased to maximize the benefit of having MPAC
members together to finalize recommendations.
Position statements and policy recommendations
made by the MPAC are approved by the WHO Dir-
ector-General, and will be formally issued and dissemi-
nated to WHO Member States by WHO-GMP.
Conclusions and recommendations from MPAC meet-
ings are published in the Malaria Journal as part of this
series.
MPAC will provide suggestions for the agenda for its
next meeting to the WHO-GMP Secretariat. Feedback
will also be given to and received from the global mal-
aria community at the RBM Board meeting in December
2012, and through the publication of, and correspond-
ence, regarding this article.
On-going engagement with and attendance by inter-
ested stakeholders at MPAC meetings was strongly
encouraged; MPAC members were pleased by the diver-
sity and increase in the number of observers in attend-
ance at the September meeting [46] and encouraged
WHO-GMP to continue its outreach. In addition to
open registration for MPAC meetings, which will con-
tinue, and attendance by four standing observers (RBM,
the Global Fund, UNICEF, Office of the UN Special
Envoy for malaria), the active participation of seven ro-
tating NMCP representatives, and all six WHO Regional
Malaria Advisors, at the September 2012 and future
meetings was strongly welcomed.
Conclusion
The meeting feedback received from participants and
observers, and MPAC members themselves, was very
positive. Having only met twice to date, MPAC is still in
the process of orienting itself to best serve the needs of
the global malaria community. However, the format
of MPAC meetings and its feedback loops with other
advisory bodies and stakeholders is beginning to take
shape. WHO-GMP and the MPAC continue to strong-
ly welcome feedback, support, and suggestions forimprovement to MPAC meetings from the global mal-
aria community.
The next meeting of the MPAC will take place from
13 to 15 March 2013 in Geneva, Switzerland. Further in-
formation including the agenda and details on how to
register will be made available in early 2013 on the
WHO-GMP website for MPAC [4].
Endnotes
aThe complete set of all MPAC September 2012
meeting-related documents including background
papers, presentations, and member declarations of inter-
est can be found online at http://www.who.int/malaria/
mpac/sep2012/en/index.html.
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